Delving into the Latest Updates on LY-3185643 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

LY 3185643, LY3185643

Target

GCGR

Action

agonists

Mechanism

GCGR agonists(Glucagon receptor agonists)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Eli Lilly & Co.

Active Organization-

Inactive Organization

Eli Lilly & Co.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The study involves a single dose of LY3143753 or LY3185643, given as an injection into the abdomen. The study will evaluate the effects of the LY3143753 or LY3185643 on your body. The study is approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to the start of the study. This study involves Part A (LY3143753) and Part B (LY3185643). Participants may only enroll in one part and at one dose level.

Start Date01 Jan 2015

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with LY-3185643

Login to view more data

100 Translational Medicine associated with LY-3185643

Login to view more data

100 Patents (Medical) associated with LY-3185643

Login to view more data

100 Deals associated with LY-3185643

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02951780 (CTgov)	Phase 1	-	23	LY3185643 (10 ug LY3185643)	lkjsyruego(eyomkaatkz) = xogbdzfzig psgcmoxtyw (blodksumvh, 49) View more	-	30 Sep 2019
				LY3185643 (25 ug LY3185643)	lkjsyruego(eyomkaatkz) = vqfixqqjwx psgcmoxtyw (blodksumvh, 36) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data